Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 812 results for "novartis ag"

Novartis Ramps Up Heart Drug Spending as Top Seller Goes Generic
Bloomberg

Novartis Ramps Up Heart Drug Spending as Top Seller Goes Generic

Novartis AG is ramping up marketing efforts for the heart drug Entresto, one of two new medicines essential to generating revenue as the company's bestseller faces generic competition. The Swiss drugmaker will spend an additional $200 million to ... Bloomberg, 4 days ago

61 images for novartis ag

CTV News, 4 days ago
Bidness Etc, 5 days ago
CTV News, 4 days ago
The Nation Pakistan, 2 days ago
Pakistan Today, 3 days ago
Pharmaceutical Tech.com, 1 week ago
Jutia Group, 1 week ago
Jutia Group, 1 week ago
srnnews.com, 1 week ago
Share Market Updates, 2 weeks ago

Novartis AG (NVS) Joseph Jimenez on Q2 2016 Results - Earnings Call Transcript

Novartis AG (NYSE: NVS ) Q2 2016 Earnings Call July 19, 2016 8:00 am ET Executives Joseph Jimenez - Chief Executive Officer Samir Shah - Global Head-Investor Relations Harry Kirsch - Chief Financial Officer Vasant Narasimhan - ...
 Seeking Alpha4 days ago Novartis AG 2016 Q2 - Results - Earnings Call Slides  Seeking Alpha4 days ago Edited Transcript of LONN.S earnings conference call or presentation 20-Jul-16 12:30pm GMT  Yahoo! Finance2 days ago

Novartis Profit Declines as Competition Hurts Cancer Drug Sales

(Bloomberg) -- Novartis AG's second-quarter earnings declined 3 percent asthe company grapples with tumbling sales of its cancer medicine Gleevecand invests in new products like heart drug Entresto and Cosentyx for psoriasis. Profit fell to $1.23 ...
 La Repubblica4 days ago Novartis Profit Falls as Competition Hurts Cancer Drug Sales (1)  La Repubblica4 days ago
Pharmaceutical Tech.com

FDA Spurns Novartis AG's Copy of Amgen Blockbuster Neulasta

U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday. Vasant Narasimhan, head of development at Novartis ...
 BioSpace4 days ago U.S. FDA panel supports Novartis version of Amgen arthritis drug  Reuters UK1 week ago Stock Update: Amgen Inc (NASDAQ:AMGN) U.S. FDA panel supports Novartis version of Amgen arthritis drug  MoneyShow.com1 week ago FDA Panel Supports Novartis Biosimilar of Etanercept  The-Rheumatologist.org1 week ago
[x]  
4 Traders

Novartis Releases Profit Warning

Swiss pharmaceutical giant Novartis AG lowered its guidance for profit for the full year as it increases its investment in its new drug for heart failure to offset dropping sales of Gleevec its blockbuster cancer drug. Joe Jimenez the CEO at ...
 Ticker Report4 days ago NOVARTIS : Warns on Profit as It Boosts Investment in Heart-Failure Pill Entresto -- Update  4 Traders4 days ago NOVARTIS : world's top drugmaker, plays down Brexit threat  4 Traders4 days ago NOVARTIS : Warns on Profit as Entresto Investment Weighs  4 Traders4 days ago
[x]  
Bidness Etc

Novartis AG (ADR) 2Q Earnings: Here's What To Expect?

Novartis AG ( NYSE:NVS ) is scheduled to report its second-quarter of fiscal 2016 (2QFY16) earnings results on July 19, 2016, before markets open. The Street expects a significant increase in profit, however, revenue may drop as some top blockbuster ...
 Bidness Etc5 days ago Novartis 2Q Earnings: Hereand#039;s What To Expect?  Mr Top Step5 days ago
Nasdaq

Novartis' Enbrel Biosimilar Gets FDA Panel Recommendation

Novartis AG NVS announced that the FDA's Arthritis Advisory Committee has recommended an approval of the company's proposed biosimilar of Amgen's AMGN blockbuster drug, Enbrel (etanercept). The committee voted unanimously (20-0) for an approval ...
 Yahoo! Finance1 week ago
[x]  

Novartis AG Set To Become Biosimilar Pioneer By 2020

Novartis generic unit Sandoz is now playing a vital role in the research and development (R&D) of biosimilars. The efforts are part of its initiative to compensate for loss of revenue caused by the expiry of patents of blockbuster drugs and ...
 BioSpace3 days ago Equities Analysts Offer Predictions for Novartis AG's FY2016 Earnings (NVS)  Mideast Time3 days ago Jefferies Group Analysts Reduce Earnings Estimates for Novartis AG (NVS)  SleekMoney4 days ago FY2016 EPS Estimates for Novartis AG (NVS) Decreased by Jefferies Group  American Banking News - Earnings5 days ago
[x]  
The Nation Pakistan

Novartis : IGI Securities Limited - Investor Kit

(PPI-OT) Pharmaceuticals Swiss pharmaceuticals firm Novartis AG said it has stopped making tuberculosis drugs in Pakistan in a dispute over pricing, prompting fears of a health crisis due to a shortage of drugs in a country with the world's ...
 4 Traders2 days ago Pricing Dispute In Pakistan Over Novartis TB Drug Raises Concern Over Supply Shortfall  Kaiser Network.org3 days ago Pricing dispute hits supply of TB drugs in Pakistan  The Nation Pakistan3 days ago Unable to absorb inflation, many pharmacies halt production of TB drugs  Pakistan Today9 hours ago
[x]  
Zacks.com

Novartis (NVS) Tops Q2 Earnings & Sales, Expenses to Grow

Novartis AG NVS reported second-quarter 2016 core earnings of $1.23 per share. On an adjusted basis, earnings were $1.22 per share beating the Zacks Consensus Estimate of $1.18. Revenues also declined 2% to $12.5 billion but were above the Zacks ...
 Zacks.com3 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less